First-line biologics reach remission more often than methotrexate in early RA

Design

Systematic review with pairwise and network meta-analysis (29 randomised trials)

Population

13,387 methotrexate-naive adults with early rheumatoid arthritis

Primary outcome

DAS28 remission at 6 months

Effect

First-line biologic/targeted DMARD plus methotrexate vs methotrexate: risk ratio 1.62 (95% CI 1.39-1.89)

Treatment of early rheumatoid arthritis conventionally starts with methotrexate, escalating only if the target is not met. This meta-analysis of 29 randomised trials (13,387 patients) asked how starting with a biologic or targeted synthetic DMARD compares.

Starting a biologic or targeted synthetic DMARD plus methotrexate produced more DAS28 remission than methotrexate alone at six months (risk ratio 1.62, 95% CI 1.39 to 1.89), with consistent benefits at three and twelve months and on ACR50 and CDAI. The advantage was larger in trials with higher baseline disease activity and more seropositive patients. As monotherapy, only JAK inhibitors and tocilizumab clearly beat methotrexate.

The nuance matters. Higher early remission with first-line advanced therapy is real, but it does not overturn guideline practice: a methotrexate-first, treat-to-target strategy achieves similar long-term control for most patients at far lower cost, and early intensive therapy is best reserved for those with poor-prognosis markers, high disease activity and seropositivity. In resource-limited settings, that targeting is especially important.

• Meta-analysis of 29 randomised trials (13,387 patients) in methotrexate-naive early rheumatoid arthritis.
• First-line biologic or targeted DMARD plus methotrexate beat methotrexate alone for 6-month remission (risk ratio 1.62).
• Benefit was greater with higher baseline disease activity and seropositivity.
• As monotherapy, only JAK inhibitors and tocilizumab clearly outperformed methotrexate.
• Reserve first-line advanced therapy for poor-prognosis, high-activity, seropositive disease; methotrexate-first remains standard.

Why it matters

It quantifies the early gain from starting harder, while clarifying that the gain does not justify abandoning a methotrexate-first strategy for everyone.

Don't overread it

This shows higher early remission, not better long-term or cost-effective outcomes; current guidelines still recommend methotrexate first with treat-to-target escalation.

The statistics, in plain English

A risk ratio of 1.62 means markedly more patients in remission at six months, a real effect; but it compares early remission, not long-term outcome or cost, and a treat-to-target methotrexate strategy catches up for many, which is why guidelines still start with methotrexate.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.